Some of the best links we picked up around the internet
Scientists used lipid nanoparticles to deliver CRISPR-Cas9 targeting Hao1 for the treatment of primary hyperoxaluria type 1. Proof-of-concept studies...
YolTech Therapeutics reports positive clinical data for the first in vivo gene-editing therapy in primary hyperoxaluria type 1, Precision BioSciences...